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A B S T R A C T
We report the production and metabolic phenotype of a mouse line in which the Fmo5 gene is disrupted.
In comparison with wild-type (WT) mice, Fmo5/mice exhibit a lean phenotype, which is age-related,
becoming apparent after 20 weeks of age. Despite greater food intake, Fmo5/mice weigh less, store less
fat in white adipose tissue (WAT), have lower plasma glucose and cholesterol concentrations and
enhanced whole-body energy expenditure, due mostly to increased resting energy expenditure, with no
increase in physical activity. An increase in respiratory exchange ratio during the dark phase, the period
in which the mice are active, indicates a switch from fat to carbohydrate oxidation. In comparison with
WT mice, the rate of fatty acid oxidation in Fmo5/ mice is higher in WAT, which would contribute to
depletion of lipid stores in this tissue, and lower in skeletal muscle. Five proteins were down regulated in
the liver of Fmo5/mice: aldolase B, ketohexokinase and cytosolic glycerol 3-phosphate dehydrogenase
(GPD1) are involved in glucose or fructose metabolism and GPD1 also in production of glycerol 3-
phosphate, a precursor of triglyceride biosynthesis; HMG-CoA synthase 1 is involved in cholesterol
biosynthesis; and malic enzyme 1 catalyzes the oxidative decarboxylation of malate to pyruvate, in the
process producing NADPH for use in lipid and cholesterol biosynthesis. Down regulation of these
proteins provides a potential explanation for the reduced fat deposits and lower plasma cholesterol
characteristic of Fmo5/ mice. Our results indicate that disruption of the Fmo5 gene slows metabolic
ageing via pleiotropic effects.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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Flavin-containing monooxygenases (FMOs) (EC 1.14.13.8) of
eukaryotes are located in the membranes of the endoplasmic
reticulum. Humans possess ﬁve functional FMO genes [1,2], four of
which, FMO1, 2, 3 and 4, are clustered on chromosome 1, in the
region 1q24.3, whereas FMO5 is located at 1q21.1 [1]. In mouse, the
genes encoding FMOs 1, 2, 3 and 4 are clustered on Chromosome
1 and Fmo5 is on Chromosome 3 [1].* Corresponding author. Tel.: +44 02076792321.
E-mail address: e.shephard@ucl.ac.uk (E.A. Shephard).
1 Current address: Department of Biochemistry, University of Cambridge,
Cambridge CB2 1QW, UK.
2 Current address: Plasticell Ltd., Stevenage Bioscience Catalyst, Stevenage SG1
2FX, UK.
http://dx.doi.org/10.1016/j.bcp.2015.05.013
0006-2952/ 2015 The Authors. Published by Elsevier Inc. This is an open access articFMOs 1, 2 and 3 catalyze the NADPH-dependent oxygenation of
a wide array of foreign chemicals, including drugs, environmental
pollutants and dietary-derived compounds [3]. The FMO1 gene
displays little genetic variation, with only a few coding-region
single-nucleotide polymorphisms (SNPs), each of which is present
at low frequency [2,4] and does not affect catalytic activity [5]. The
majority of humans, however, are homozygous for a nonsense
mutation of FMO2, which results in the expression of a non-
functional protein [6,7], and mutations in FMO3 cause the disorder
trimethylaminuria [8], which is characterized by an unpleasant
body odour, due to defective N-oxygenation of dietary-derived
trimethylamine [9]. FMO4 has not been detected in vivo and little
is known of its substrates or activity.
Although FMO5 is highly expressed in the liver of mice [10] and
humans [11], little is known of the role of this protein. FMO5
displays few characteristics of an enzyme involved in thele under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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towards classic FMO substrates, such as methimazole [12],
trimethylamine [13] and benzydamine [14]. Knowledge of its
substrates is limited [2,15,16]: it catalyzes the N-oxygenation of
short-chain aliphatic primary amines such as N-octylamine [12]
and the S-oxygenation of S-methyl-esonarimod, an active metab-
olite of the anti-rheumatic esonarimod [15,17]. The ability of FMO5
to catalyze a Baeyer–Villiger oxidation reaction was revealed in a
study of an anti-cancer therapeutic [18].
Interindividual variation in the amount of FMO5 in human liver
has been reported [19]. This may be due to physiological effects or
to exposure to foreign chemicals, as, unlike other FMOs, FMO5 is
inducible by a number of chemicals, e.g., expression is increased in
a breast cancer cell line by the synthetic progestin R5020 [20], in
human hepatocytes by rifampin [21] and in HepG2 cells by
hyperforin [22].
Recently, through the use of a knockout (KO) mouse line, we
have shown that FMO1 plays an important role not only in drug
metabolism in vivo [23,24], but also in endogenous metabolism,
acting as a regulator of energy homeostasis [25]. A physiological
role for FMO5 is also suspected, due to the small number of
xenobiotic substrates for the enzyme and the paucity of coding-
region SNPs in the FMO5 gene. To investigate the role of FMO5 we
produced a KO mouse line in which the Fmo5 gene has been
disrupted. Here, we report the metabolic phenotype of Fmo5/
mice. This indicates that FMO5 promotes metabolic ageing, via
pleiotropic effects, including acting as a positive modulator of
cholesterol biosynthesis, and thus identiﬁes, for the ﬁrst time, a
role for this protein in endogenous metabolism.
2. Materials and methods
2.1. Gene targeting and generation of Fmo5/ mice
Genomic clones containing Fmo5 were isolated from the RPC1-
21 mouse Pac genomic library (Roswell Park Cancer Institute,
Buffalo, NY) by screening with a PCR product corresponding to the
30-UTR of human FMO5. The identity of the clones was conﬁrmed
by hybridization with the 30-UTR of mouse Fmo5 and restriction
map comparison with mouse genomic DNA. One of the clones (in a
pPAC4 vector) was analyzed by Southern blotting with Fmo5 exon-
speciﬁc PCR products as probes. This identiﬁed the appropriate
restriction fragments to be incorporated in the targeting vector and
the screening strategy to be employed at the embryonic stem (ES)
cell and animal level. A 2-kb KpnI fragment extending upstream
from a site located 150 bp upstream of the ATG translational
initiation codon and a 7-kb ApaI fragment extending downstream
from a site located 653 bp downstream of the translational
initiation codon were used as the short and long arms of homology,
respectively. These fragments were inserted on either side of a neor
cassette within a pPN targeting vector to produce the ﬁnal
targeting construct (Fig. 1A). pPN was modiﬁed from pPNT (a gift of
VLJ Tybulewicz, MRC NIMR, Mill Hill, London) by excision of the
HSV-1tk cassette.
E14 ES cells (derived from the 129/Ola mouse strain) were
transfected, by electroporation, with the linearized targeting
construct. Recombination between the homologous regions of
the targeting construct and the Fmo5 genomic locus (Fig. 1A)
would result in the replacement of exon 2, which encodes the ATG
translation initiation codon and the FAD-binding domain of FMO5,
by the neor cassette, rendering the allele null. After positive
selection of ES cells with G418, correctly targeted clones were
identiﬁed by both PCR and Southern-blot analysis (Fig. 1B). ES cells
in which the Fmo5 gene had been correctly targeted were injected
into C57BL/6 mouse blastocysts [26]. Blastocysts were then
implanted into the uterus of a pseudopregnant CD-1 mouse [26].Male chimeric progeny were crossed with WT female C57BL/6
mice to test for germline transmission of the ES cell mutation.
Progeny arising from germ cells derived from the injected ES cells,
i.e., agouti coloured, were genotyped as described below and in
Fig. 1C. Progeny that were heterozygous for the disrupted Fmo5
gene were backcrossed with WT C57BL/6 mice for eight genera-
tions to establish a congenic KO mouse line. Offspring were
genotyped, by PCR analysis of mouse tail DNA, as described
previously [26], using the primer pair 2a-A1r (2a, forward primer 50
CCTTTGCGTTTACGGAAGAAGGGTGC 30; A1r, reverse primer 50
TTGCCTGCATGCATGTTTATGTGC 30), to conﬁrm the presence of the
targeted allele (2 kb) or the wild-type allele (1 kb) (Fig. 1C).
2.2. Animal maintenance, body weight and food intake measurements
Males and females from the congenic mouse line, which were
heterozygous for the disrupted Fmo5 gene, were mated to produce
the homozygous KO mice (Fmo5/) used in this study. The
absence of the FMO5 protein in the KO animals was conﬁrmed by
western blotting (Fig. 1D). WT C57BL/6 mice were used as controls.
Mice were bred at UCL and fed a standard chow diet (Teklad Global
18% Protein Rodent Diet, Harlan Laboratories, Inc., Madison, WI).
For body weight measurement, animals were housed at a
maximum density of ﬁve per cage and weight was recorded up
to 52 weeks of age. For food intake measurement, animals were
housed at a density of four per cage and food weighed before and
after each 72-h period for 10 weeks. Tissue, plasma and urine
samples were collected between 10:30 a.m. and 12:00 noon.
Animal procedures were carried out in accordance with the UK
Animal Scientiﬁc Procedures Act and with local ethics committee
approval and appropriate Home Ofﬁce Licences.
2.3. Morphological analysis
Sections of white adipose tissue (WAT) were stained with
haematoxylin and eosin. Diameters of adipocytes were measured
as described previously [25]. Frozen sections (12 mm) of liver were
stained with Oil Red O (Sigma–Aldrich, Poole, UK) and counter-
stained with haematoxylin.
2.4. Plasma and urine metabolites
After restriction of food for either 4 h or overnight, blood and
urine were collected between 10:30 a.m. and 12:00 noon. Blood
samples were taken from mouse tail tips and plasma was isolated,
as described [27]. Concentrations of plasma and urine metabolites,
with the exception of pyruvate, were determined at the MRC
Mammalian Genomics Unit, Harwell, Oxon, UK [27]. Pyruvate was
quantiﬁed by NMR spectroscopy in plasma samples diluted 2:1
with 0.9% saline in D2O, the latter to provide the ﬁeld/frequency
‘lock’ for the NMR spectrometer. 1H NMR spectra were recorded on
an Avance spectrometer (Bruker BioSpin GmbH, Rheinstetten,
Germany) operating at 600.44 MHz at a temperature of 300 K. Two
types of one-dimensional (1D) 1H NMR spectra were acquired. The
ﬁrst was a standard 1D NOESY presaturation (Bruker pulse
sequence noesypr1d) spectrum using the pulse sequence (RD-
908-t1-908-tm-908-acquire). For each spectrum, a total of eight
dummy scans and 128 transients were collected into 65,536 data
points over a spectral width of 20.0173 ppm, using a relaxation
delay (RD) of 2 s, and a mixing time of 100 ms. To suppress signals
from macromolecules, a second set of data was acquired using the
Carr–Purcell–Meiboom–Gill (CPMG) spin-echo experiment (Bru-
ker pulse sequence cpmgpr). The pulse sequence used was RD
[908x  (t  1808y  t)n  acquire], with RD = 2 s, t, spin-echo
delay = 400 ms and n (the number of loops) = 100, and therefore
a total spin–spin relaxation delay (2nt) of 80 ms. During the
Fig. 1. Gene targeting and generation of Fmo5/ KO mice. (A) Recombination between homologous regions (thick black lines) of the targeting construct and the Fmo5 locus
leading to the generation of the Fmo5 targeted allele, in which exon 2 is replaced by the neor cassette (neo). Exons are represented by black boxes. Primers used in PCR
screening of the G418r ES clones are depicted with black arrows (a and b). Primers used to distinguish between the WT and targeted alleles are depicted with white arrows (c
and d) (see also C). Restriction sites and probes used for Southern blot genotyping of the targeted ES clones and the mice are also shown. Not drawn to scale. (B) After PCR
screening (not shown) Southern blot analysis with (i) a neor-speciﬁc probe, (ii) a 50-internal probe, (iii) a 30-external probe further conﬁrmed the correct structure of the
targeted allele. Analysis using a vector-speciﬁc probe veriﬁed the absence of any random integrations in the targeted ES clones (data not shown). (C) Mice were genotyped by
PCR analysis of tail DNA with primers c and d (see A). Het, heterozygous knockout (Fmo5+/); KO, homozygous knockout (Fmo5/); WT, wild type. (D) Western blot of liver
proteins showing lack of FMO5 expression in Fmo5/ mice (KO) compared with WT mice (WT).
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suppression of the water peak. Other parameters were as above. All
NMR spectra were processed using MNova software v9.1.0
(Mestrelab, Santiago de Compostela, Spain) with zero-ﬁlling to
65,536 data points, apodisation with a line-broadening of 0.3 Hz,
automated baseline correction and phasing (with manual override
as required) and referencing to the alpha anomeric proton of
D-glucose at 5.233 ppm. Quantiﬁcation of pyruvate in the NOESY
presaturation spectra was made relative to the concentration of
glucose (Cg) in each sample, determined by biochemical analysis.
Speciﬁcally, the area for the methyl signal for pyruvate at 2.37 ppm
was divided by 3 to obtain the one-proton equivalent signal area,
Apyr. This was then compared with the one-proton signal area
calculated for D-glucopyranose, Ag. To obtain the latter ﬁgure, the
area of the alpha anomeric proton of D-glucopyranose at 5.233 ppm
was divided by the known fraction of the alpha pyranose in
solution: 0.376 [28]. Pyruvate concentration was then calculated
as Cg  Apyr/Ag. All signal area measurements were done by
manual integration in MNova.
2.5. Glycogen measurements
Liver glycogen was measured by the glucose oxidase assay
method as described by Huijing [29].
2.6. Metabolic rate measurements
30-week-old male mice were housed individually in Oxymax
cages (Columbus Instruments, Columbus, OH) at 27 8C and allowed
to acclimatize for 24 h. VO2 and VCO2 were measured, over a 72-h
period, and heat, respiratory exchange ratio (RER) and resting
energy expenditure (REE) calculated, as described previously [25].
2.7. Assessment of voluntary exercise
30-week-old male mice were housed individually in an
activity wheel chamber system (Lafayette Instrument Co.,
Lafayette, IN). Activity was measured every minute during the
dark phase and every hour during the light phase for a period of
seven days. Data were analyzed using the Lafayette software
excel ofﬁce add-in and the hourly average of the interval count
data was calculated to determine the total wheel revolutions per
hour per mouse.
2.8. Fatty acid oxidation
Fatty acid oxidation was measured using [U-14C]palmitate (GE
Life Sciences, Little Chalfont, Bucks, UK), essentially as described
[30].
2.9. Proteomic analysis
Livers from ﬁve KO and ﬁve WT mice were perfused in situ, via
the hepatic vein, with cold phosphate-buffered saline to remove
excess haemoglobin. Livers were ﬂash frozen in liquid nitrogen and
stored at 80 8C. Samples were prepared, and differential protein
expression between Fmo5/ and WT liver samples was quantiﬁed
by ﬂuorescence two-dimensional difference gel electrophoresis
(2D-DIGE), followed by image analysis, essentially as described
[31]. The criteria for identifying differentially expressed proteins
were >1.5-fold difference in spot intensity and a statistical t-test
P < 0.01. Selected protein spots were picked using an Ettan Spot
Picker system (GE Life Sciences). Proteins were digested with
trypsin and identiﬁed by liquid chromatography tandem mass
spectrometry (MS), essentially as described [32]. Raw MS data
were searched against the IPI mouse database (20100214; 56,737sequences) using the Mascot search engine. Identiﬁcations were
accepted when two or more usable unique peptide sequences were
matched to a protein, using a signiﬁcance threshold of >0.05 and
an ion score cut off of >20.
2.10. Western blot analysis
Liver tissue was homogenized in ice-cold 1% Triton X-100,
140 mM NaCl, 10 mM Tris pH8, 1 mM EDTA, 1 mM PMSF
containing HaltTM Protease and Phosphatase Inhibitor Cocktail
(Thermo Fisher Scientiﬁc, Loughborough, Leicestershire, UK) at
25 Hz for 30 s in a Tissue Lyser II (Qiagen, Crawley, Surrey, UK).
Samples were left to cool on ice for 1 min and homogenized for a
further 30 s at 25 Hz. Homogenates were rotated on a spinning
wheel for 15 min at 4 8C, then centrifuged at 12,000  g for
20 min at 4 8C. Supernatants were analyzed by SDS-PAGE and
western blotting. For FMO5, the blot was incubated with Rabbit
anti-FMO5 polyclonal Antibody, 13699-1-AP (Proteintech, Chi-
cago, IL) and then with a horse radish peroxidase-conjugated
secondary antibody (Donkey Anti-Rabbit IgG H&L (HRP)),
ab97064 (Abcam, Cambridge, MA). Blots were developed using
enhanced chemiluminescence (ECL), as described [33], using 4-
iodophenylboronic acid (Thermo Fisher Scientiﬁc) as an enhanc-
er. Signal was detected using an LAS-1000 image reader (Fujiﬁlm
UK, Ltd., Bedford, Beds, UK) with software version 2.6. For malic
enzyme 1 (ME1) liver tissue was homogenized at 4 8C in RIPA lysis
buffer (Sigma–Aldrich) containing HaltTM Protease and Phos-
phatase Inhibitor Cocktail. Homogenates were agitated continu-
ously for 2 h at 4 8C, then centrifuged at 12,000  g for 20 min at
4 8C. Supernatants were analyzed by SDS-PAGE and western
blotting. The blot was incubated with Anti-ME1 antibody,
ab84561 (Abcam). The secondary antibody was Alexa Fluor
800 goat anti-rabbit IgG (Life Technologies, Paisley, Scotland,
UK). For loading control the blot was incubated with a
monoclonal anti-mouse beta-actin (Sigma–Aldrich) and an
anti-mouse Alexa Fluor 680 secondary antibody (Life Technolo-
gies), then imaged using an Odyssey system (LI-COR Biosciences
Ltd., Cambridge, Cambs, UK).
2.11. Quantitative real-time (qRT) PCR
Liver RNA was isolated using Tri Reagent (Sigma–Aldrich) and
cDNA synthesized using a Precision QScript Reverse Transcriptase
kit (Primer Design Ltd, Southampton, Hants, UK). qRT PCR was
performed as described previously [25] and mRNAs were
quantiﬁed by the DDCT method [34]. Primer sequences forward
(F) and reverse (R) were: Srebp2F 50 TGAAGGACTTAGTCATGGG-
GAC 30 and Srebp2R 50 CGCAGCTTGTGATTGACCT 30, Hmgcs1F 50
CCTGGACCGCTGCTATTCT 30 and Hmgcs1R 50 CAGTTTACCAA-
TATGGTGAGTGAAAGA 30, HmgcrF 50 CCGAATTGTATGTGGCACTGT
30 and HmgcrR 50 TTATCTTTGATCTGTTGTGAACCAT 30, SSF 50
ATGGAGTTCGTCAAGTGTCTAGG 30 and SSR 50 GCTGCCGTAT-
GTCCCCATC 30, Cyp7a1F 50 ACACATACCAATAAGAAGAGCATTT 30
and Cyp7a1R 50 GACCAGAATAACCTCAGACTCATA 30, Cyp27a1F 50
GATGAGACAGGAGGGCAAGTA 30 and Cyp27a1R 50 TGCGATGAA-
GATCCCATAGGT 30, SRB1F 50 TTCTGGGGTCTTCACTGTCTT 30 and
SRB1R 50 TCTTGCTGAGTCCGTTCCAT 30, Abcg5F 50 GTCATCGC-
CACGGTCATTT 30 and Abcg5R 50 AGAGCAGCAGAGAAATATCCAAA
30, Abcg8F 50 GCAGATTCAATTTAATGGACACCTT 30 and Abcg8R, 50
CATAGAGTGGATGCGAGTTCAG 30, Abcb11F 50 TGGTCAATTCCTT-
CACTAACATCT 30 and Abcb11R 50 AAGCGAATCCTGTCAGCATTT 30,
ME1F 50 GGCCTGCGGACTGAGACACATCGA 30 and ME1R 50
AAACAGTGGCCATCTTTTCTTTGTA 30.
A geNormTM kit and geNorm software (Primer Design Ltd.) were
used to determine the most suitable housekeeping gene for use as
internal reference.
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Microsomal membrane vesicles were isolated from liver and
squalene synthase activity was measured using farnesyl pyrophos-
phate-[1-3H(N)], triammonium salt (Perkin Elmer, Seer Green,
Bucks, UK), as described previously [35], except that the incubation
time was 45 min. Radioactive squalene was resolved by thin-layer
chromatography, using 5% toluene in hexane, and revealed by
incubating the plate with iodine pearls. The spot was marked and the
plate left overnight to release iodine. The spot was then scraped into
scintillation ﬂuid and radioactive squalene measured by liquid
scintillation spectrometry. Protein was assayed using the DC protein
assay (Bio-Rad Laboratories Ltd., Hemel Hempstead, Herts, UK).
2.13. Quantiﬁcation of acetyl-CoA
For total hepatic acetyl-CoA, frozen liver (0.1 g) was homogenized
on ice in 0.5 ml of ice-cold 5% (w/v) perchloric acid (PCA) using an
UltraTurrax tissue disintegrator. For cytosolic acetyl-CoA, liver was
homogenized in ice-cold 225 mM mannitol, 75 mM sucrose, 0.1 mM
EDTA, 5 mM MOPS pH7.4 using a Potter Elvehjem homogenizer. The
homogenate was centrifuged at 700  g for 10 min and the
supernatant was centrifuged at 12,000  g for 10 min to pellet
mitochondria. The postmitochondrial supernatant was centrifuged
at 100,000  g for 90 min. All centrifugation steps were performed at
4 8C. The resulting supernatant was acidiﬁed by adding PCA to a ﬁnal
concentration of 5%. Acetyl-CoA was measured as described [36].
2.14. Statistical analysis
Statistical analyses were performed using an unpaired, two-
tailed t-test or one-way ANOVA, as appropriate. Signiﬁcance level
P < 0.05.Fig. 2. Fmo5/mice exhibit a lean phenotype. (A) Body weight plotted as means  SEM (
WT and Fmo5/ (KO) mice. (C) Ratio of weight of EWAT to body weight of WT and Fmo5/
(WT), 8 (KO). Data are expressed as means  SEM. **P < 0.01; ****P < 0.0001. (D) Sections of e
and eosin. Scale bar = 100 mm. (E) Food intake expressed as cumulative food intake in gra3. Results
3.1. Fmo5/ mice exhibit an age-related lean phenotype, with
reduced gains in body weight and fat deposits
Fmo5/ mice appeared healthy and bred normally. From birth
to about 20 weeks of age the weight of male KO and WT mice fed a
standard chow diet was similar (Fig. 2A). From 20 weeks of age
both KO and WT mice continued to gain weight. However, from
this age the rate of weight gain of the KO mice was less than that of
WT mice (Fig. 2A), and by 30 weeks the weight of KO mice
(33.92  0.53 g, n = 7) was 10% less than that of WT animals
(37.50  0.85 g, n = 8) (P < 0.01). The difference in weight increased
with age and by 52 weeks KO mice (35.46  0.50 g, n = 5) weighed
17% less than WT mice (42.96  0.66 g, n = 5) (P < 0.001). Female
mice displayed a similar age-related difference in weight gain (data
not shown) and at 30 weeks of age the weight of female KO mice
(23.79  0.71 g, n = 10) was 14% less than that of WT mice
(27.75  0.81 g, n = 6) (P < 0.01). As age-related differences in weight
gain between KO and WT mice were similar in both male and female
mice, subsequent analysis was done on male animals unless stated
otherwise.
At 30 weeks of age, the KO mice were leaner than WT mice, had
less subcutaneous and inguinal fat and less fat surrounding
internal organs (Fig. 2B). The epididymal fat pads of KO mice
(0.47  0.05 g, n = 8) weighed 63% less than those of WT mice
(1.27  0.11 g, n = 11) (P < 0.0001). At 10 weeks of age the ratio of the
weight of epididymal white adipose tissue (EWAT) to body weight of
WT and KO mice was similar (Fig. 2C). In WT mice it increased
signiﬁcantly with age (P < 0.01), reaching 0.036  0.002 (n = 11) by
30 weeks (Fig. 2C). In contrast, in KO mice the ratio was relatively
constant with age and at 30 weeks was 0.016  0.002 (n = 8), 56% less
than that of WT mice (P < 0.0001). Inactivation of the Fmo5 geneWT, n = 8; KO, n = 7), *P < 0.05, **P < 0.01. (B) Internal abdominal view of 30-week-old
(KO) mice. 10 week: n = 4 (WT), 3 (KO); 20 week: n = 10 (WT), 5 (KO); 30 week: n = 11
pididymal WAT of 30-week-old WT and Fmo5/ (KO) mice stained with haematoxylin
ms per g of body weight of WT and Fmo5/ (KO) mice. n = 8 (WT), 7 (KO).
Fig. 3. Fmo5/ mice have lower plasma concentrations of glucose, cholesterol and
pyruvate. (A) Plasma concentration of glucose in 10- and 30-week-old male and 30-
week-old female WT and Fmo5/ (KO) mice. 10 week: n = 6 (WT), 3 (KO); 30-week
male: n = 19 (WT), 11 (KO); 30-week female: n = 9 (WT), 13 (KO). (B) Plasma
concentration of total cholesterol in 10- and 30-week-old male and 30-week-old
female WT and Fmo5/ (KO) mice. 10 week: n = 11 (WT), 8 (KO); 30-week male:
n = 23 (WT), 18 (KO); 30-week female: n = 6 (WT), 10 (KO). (C) Plasma
concentration of pyruvate in 15- and 30-week-old male WT and Fmo5 (KO)
mice, n = 4 (15 week), 5 (30 week). Data are expressed as means  SEM. *P < 0.05,
**P < 0.01, ****P < 0.0001.
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body weight, which is accompanied by a lack of increase in fat depot
size as the KO mice age.
At 30 weeks of age the diameter of epididymal adipocytes from
the KO mice (57.22  1.60 mm, n = 3) was less than that of those
from WT mice (78.80  2.88 mm, n = 3) (P < 0.01) (Fig. 2D), equiva-
lent to a decrease in cell volume of 62%. This corresponds closely to
the 63% decrease in the weight of epididymal fat pads of the KO mice,
indicating that the difference in weight of epididymal fat between KO
and WT mice was due to a difference in adipocyte volume.
Over a 12-week period from 16 weeks of age, the cumulative
intake of food by KO mice was 28% more than by WT mice, when
measured per g of body weight (Fig. 2E). The increased intake of
food by the KO mice was evident from 20 weeks of age, which
coincides with the time at which their rate of weight gain begins to
slow in comparison with WT mice (Fig. 2A). At 30 weeks of age,
although the FMO5 KO mice weighed 10% less than WT animals,
their food intake per animal per day was 14% more than that of WT
mice (data not shown). Therefore, the reduction in the rate of
weight gain and in the amount of WAT in the KO mice occurred
despite an increase in food intake.
3.2. Fmo5/mice have no impairment of lipid import into or export
from adipocytes
There were no signiﬁcant differences between 30-week-old KO
and WT mice in the plasma concentrations of triglycerides (KO,
0.83  0.03 mmol/l, n = 7; WT, 0.89  0.07 mmol/l, n = 10), non-
esteriﬁed fatty acids (NEFA) (KO, 0.88  0.09 mmol/l, n = 4; WT,
0.74  0.07 mmol/l, n = 4) or glycerol (KO, 0.35  0.02 mmol/l, n = 4;
WT, 0.38  0.01 mmol/l, n = 4), indicating that the reduced accumu-
lation in Fmo5/ mice of adipose tissue triacylglycerol was not the
result of impaired lipid import into or export from adipocytes. The
plasma concentration of NEFA after a 16-h fast increased to
1.40  0.10 mmol/l (n = 4) in KO mice and to 1.36  0.13 mmol/l
(n = 4) in WT mice. Thus, despite having less stored fat, Fmo5/mice
were able to mobilize triglycerides from WAT normally in response to
an overnight fast.
3.3. Fmo5/ mice do not increase ectopic fat stores
Histological analysis revealed that there was no difference in
the amount of lipid present in the livers of KO and WT mice (data
not shown). This indicates that the decreased accumulation of
triglycerides in WAT of Fmo5/mice was not a consequence of an
increase in ectopic fat storage and suggests that export of
triglycerides from liver is not impaired in these animals.
3.4. Fmo5/ mice have reduced plasma glucose and cholesterol
The plasma concentration of glucose in 10-week-old male
Fmo5/ and WT mice was similar (Fig. 3A). At 30 weeks of age it
was unchanged in WT mice (10.92  0.23 mmol/l, n = 19), but was
lower in KO mice (9.07  0.63 mmol/l, n = 11) (P < 0.05). Thirty-
week-old female KO mice also had lower plasma glucose than their
WT counterparts (Fig. 3A). At 30 weeks, both KO and WT male mice
responded to a 12-h overnight withdrawal of food by decreasing their
plasma glucose. Again, the plasma concentration of glucose in KO
mice (6.60  0.09 mmol/l, n = 5) was signiﬁcantly lower than in WT
mice (7.90  0.35 mmol/l, n = 8) (P < 0.01). The urinary concentra-
tion of glucose of KO (1.69  0.15 mmol/l, n = 3) and WT mice
(2.12  0.51 mmol/l, n = 3) was similar, indicating that the reduced
plasma glucose of KO mice was not a consequence of enhanced
urinary excretion of glucose.
There was no difference in liver glycogen content of KO
(66.83  4.88 mg/g liver, n = 5) and WT (63.84  5.16 mg/g liver,n = 6) mice. Thus, the reduction in plasma glucose in the Fmo5/
mice is not due to increased storage of glucose in the form of glycogen in
the liver or to decreased mobilization of glucose from liver glycogen.
The plasma concentration of total cholesterol in 10-week-old
male KO and WT mice was similar (Fig. 3B). At 30 weeks of age the
concentration in WT mice had increased, but in KO animals
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30-week-old mice, plasma cholesterol in female WT animals was
lower than in male WT animals and similar to that in male KO mice
(Fig. 3B). As was the case for male mice, in 30-week-old female
mice plasma cholesterol was lower in KO than in WT animals
(Fig. 3B). In 30-week-old male animals plasma concentrations of
both HDL (KO, 1.61  0.21 mmol/l, n = 7; WT, 2.43  0.10 mmol/l,
n = 10) (P < 0.01) and LDL (KO, 0.36  0.02 mmol/l, n = 7; WT,
0.48  0.02 mmol/l, n = 10) (P < 0.001) were lower, by 34% and
25% respectively, in the KO mice. There was no signiﬁcant difference
between KO and WT mice in the ratio of total cholesterol to HDL.
3.5. Fmo5/ mice have enhanced energy expenditure
Total energy expenditure, as measured by oxygen consumption,
was signiﬁcantly higher in Fmo5/ mice than in WT animals in
both the light and dark phases (Fig. 4A), which suggests that
oxidation of fuel substrates is continuously higher in the KO mice.
Resting energy expenditure (REE), a measure of basal metabolic
rate plus energy expended in processing food, also is higher in KO
than in WT mice (Fig. 4B). More than 80% of the enhanced whole-
body energy expenditure of Fmo5/mice is thus attributable to an
increase in REE.
The respiratory exchange ratio (RER) reﬂects the relative
contributions of carbohydrate and fat oxidation to total energy
expenditure. During the light phase the RER for FMO5 KO mice
(0.943  0.007) was similar to that for WT mice (0.950  0.006)
(Fig. 4C). During the dark phase the RER of WT animals remained the
same as that for the light phase. In contrast, in the dark phase the
RER of the KO mice increased to 0.989  0.006 (Fig. 4C). The resultsFig. 4. Fmo5/mice have enhanced energy expenditure, but no increase in voluntary exe
(B) REE. (C) RER for light, dark and combined light and dark phases. Light phase (L, 07:0
period for 30-week-old male WT (n = 6) and Fmo5/ (KO) (n = 6) mice. Values are means
of 30-week-old male WT and Fmo5/ (KO) mice was assessed over seven days. Actogramindicate that during the light phase the proportion of carbohydrate
and fat oxidized by KO and WT mice is similar and for WT mice
remains the same during the dark phase. However, during the dark
phase the KO mice increase the proportion of carbohydrate
oxidized. Urinary concentrations of urea and creatinine were
similar in KO and WT mice (data not shown), indicating that the
KO mice did not increase protein breakdown to maintain energy
balance.
3.6. Fmo5/ mice do not exhibit increased physical activity
The physical activity of Fmo5/ and WT mice, as assessed by
voluntary wheel running over a period of seven days, was similar,
with a normal increase in nocturnal activity for both sets of mice
(Fig. 4D). There was no signiﬁcant difference between the KO and
WT mice in either the distance run or the speed of running (data
not shown). Therefore the enhanced whole-body energy expendi-
ture of Fmo5/mice was not a consequence of increased physical
activity.
3.7. In Fmo5/ mice fatty acid oxidation is increased in EWAT and
decreased in skeletal muscle
At 20 weeks of age, the time at which KO mice begin to show a
reduction in weight gain, the rate of oxidation of [14C]palmitate in
EWAT of KO animals (219  30 mmol palmitate oxidized/fat pad/h,
n = 4) was 55% more than that of WT animals (141  17 mmol
palmitate oxidized/fat pad/h, n = 10) (P < 0.05). The increased rate of
fatty acid oxidation would contribute to depletion of lipid stores in
EWAT of KO mice.rcise. (A) Energy expenditure in the light, dark and combined light and dark phases.
0 to 19:00), dark phase (D, 19:00 to 07:00). Parameters were measured over a 72-h
  SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P< 0.0001. (D) Voluntary wheel running
 shows average interval count/h  SEM for a single day.
Fig. 5. Five key metabolic enzymes are down regulated in the liver of Fmo5/ mice. Relative abundance of aldolase B (ALDOB) (A), glycerol 3-phosphate dehydrogenase
(GPD1) (B), ketohexokinase (KHK) (C), malic enzyme 1 (ME1) (D) and HMG-CoA synthase 1 (HMGCS1) (E) in liver of WT and Fmo5/ (KO) mice determined via proteomic
analysis. (F) Western blot analysis of liver lysates of WT and Fmo5/ (KO) mice. The blot was incubated with antibodies against ME1 and actin, as a loading control, and
developed as described in Section 2.
Table 1
Relative difference in the abundance of mRNAs in the liver of WT and Fmo5/mice.
mRNA Relative
expression,
KO to WT
Cholesterol biosynthesis
HMG CoA synthase (HMGCS1) 1.71  0.47
HMG CoA reductase (HMGR) 2.41  0.46*
Squalene synthase (SS) 3.23  0.57*
Sterol responsive element binding protein (SREBP-2) 2.45  0.28*
Cholesterol uptake and transport
Scavenger receptor (SR-B1) 1.24  0.21
Abcg 5 1.74  0.26
Abcg 8 1.60  0.25
Bile acid synthesis
Cholesterol 7a hydroxylase (CYP7a1) 1.22  0.49
Cholesterol 27a hydroxylase (CYP27a1) 0.78  0.20
The abundance of each mRNA was determined by qRT-PCR. Data are presented as
relative abundance in Fmo5/ (KO) compared to WT mice. Values are expressed as
means  S.E.M, n = 6–9.
* P < 0.05.
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major energy source. In 20-week-old mice the rate of [14C]palmi-
tate oxidation in cardiac muscle was similar in KO and WT mice
(data not shown). However, in resting soleus muscle it was 32%
lower in KO (1255  74 mmol palmitate oxidized/g/h, n = 5) than in
WT animals (1843  224 mmol palmitate oxidized/g/h, n = 4)
(P < 0.05).
3.8. Proteins involved in carbohydrate metabolism or in cholesterol or
lipid synthesis are down regulated in Fmo5/ mouse liver
The liver plays an important role in metabolic homeostasis
and is an organ in which the Fmo5 gene is highly expressed
[10]. To gain an insight into the basis of the metabolic phenotype
of the Fmo5/mice we performed a proteomic analysis of liver to
identify proteins that differed in abundance between KO and WT
mice and, thus, might contribute to the phenotype. Five proteins
were down regulated in KO animals. All are enzymes involved in
carbohydrate metabolism or in cholesterol or lipid biosynthesis
(Fig. 5): aldolase B and ketohexokinase, involved in glucose and
fructose metabolism; glycerol 3-phosphate dehydrogenase
(GPD1), a cytosolic protein important for the production of
NAD+ and for transporting reducing equivalents from the cytosol
to mitochondria; b-hydroxy-b-methylglutaryl-CoA (HMG-CoA)
synthase 1, a cytosolic protein involved in cholesterol biosynthesis;
and cytosolic malic enzyme (ME1), a lipogenic enzyme that
catalyzes the oxidative decarboxylation of malate to pyruvate, in
the process producing NADPH for use in lipid and cholesterol
biosynthesis. Down-regulation of aldolase B, a glycolytic enzyme,
and ME1 would be expected to result in a decrease in the production
of pyruvate. This is supported by the ﬁnding that the plasma
concentration of pyruvate in 30-week-old animals is 57% lower in
Fmo5/mice than in WT animals (Fig. 3C). The difference in plasma
pyruvate is age related, as in 15-week-old animals the concentration
is the same in KO and WT mice (Fig. 3C).The lower abundance of HMG-CoA synthase 1 in the liver of KO
mice was not the result of a difference in the abundance of the
corresponding mRNA (Table 1). In contrast, the mRNAs for two
other enzymes involved in cholesterol biosynthesis, HMG-CoA
reductase and squalene synthase, were more abundant in the livers
of KO than of WT mice, as was the mRNA for sterol regulatory
element-binding protein-2 (SREBP-2), a transcription factor that
up-regulates the transcription of genes encoding several enzymes
involved in cholesterol synthesis (Table 1). Although the abun-
dance of the mRNA for squalene synthase was greater in the livers
of KO than of WT mice, neither the amount nor activity of the
encoded protein differed signiﬁcantly between KO and WT mice
(data not shown). The abundance in liver of mRNAs for proteins
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synthesis did not differ between KO and WT mice (Table 1).
All the carbon in cholesterol is derived from acetate, via acetyl-
CoA. The amounts of total and cytosolic acetyl-CoA in liver were not
signiﬁcantly different between KO and WT mice (data not shown).
Western blotting revealed that, in contrast to WT mice, in
Fmo5/ mice ME1 was not detectable in the liver (Fig. 5F).
However, as was the case for HMG-CoA synthase 1 (see above), the
abundance of the corresponding ME1 mRNA in the livers of KO and
WT mice was not signiﬁcantly different. Therefore down regula-
tion of the expression of HMG-CoA synthase 1 and ME1 in Fmo5/
mice is mediated at the translational or post-translational level.
4. Discussion
Mice in which the Fmo5 gene had been inactivated appeared
healthy but exhibited a lean phenotype, which was age-related,
becoming apparent only at about 20 weeks of age. From this age
WT mice continued to increase body weight and this was
accompanied by increases in the amount of lipid stored in WAT
and in the plasma concentration of cholesterol. In contrast, as they
aged Fmo5/ mice, despite eating more than their WT counter-
parts, were resistant to weight gain and their fat deposits and
plasma cholesterol remained the same as that of 10-week-old
mice. In addition, at 30 weeks of age the plasma concentration of
glucose was lower in KO than in WT mice. The main characteristics
of the phenotype, reduced weight gain and lower plasma
concentrations of glucose and cholesterol, were evident also in
female Fmo5/ mice and, thus, the phenotype is gender-
independent.
Fmo5/ mice suffered no loss of appetite or decrease in
physical activity, indicating that the phenotype is unlikely to be a
consequence of illness or general malaise. Indeed, disruption of the
gene encoding FMO5 resulted in a relatively ‘healthy’ phenotype,
with mice being protected against a number of age-related
metabolic changes that could adversely affect wellbeing. The
increased food consumption of the Fmo5/ mice was likely a
response to the lower amounts of fat reserves of these animals.
The lean phenotype of Fmo5/ mice was associated with
enhanced whole-body energy expenditure, most of which was due
to higher REE, with no increase in physical activity. The basis of the
enhanced REE is unclear.
The increased rate of fatty acid oxidation in EWAT of KO mice at
20 weeks of age would contribute to the depletion of triglyceride
stores in this tissue and, hence, to reduction of adipocyte volume.
At the same age, the lower rate of fatty acid oxidation in skeletal
muscle of KO than of WT mice suggests a switch to increased use of
carbohydrate as fuel in this tissue in KO mice. This is supported by
the RER of 30-week-old mice, which indicates that during the dark
phase, the period in which the mice are most active, the ratio of
carbohydrate to fat utilized as fuel was higher in KO than in WT
mice. The increased use by KO mice of carbohydrate as fuel is
possibly a response to the diminished stores of lipid in WAT of
these animals and might also contribute to their lower plasma
concentration of glucose. In WT mice the Fmo5 gene is not
expressed in WAT or skeletal muscle (data not shown), indicating
that the effects in these tissues of disruption of Fmo5 are indirect.
Three of the proteins down regulated in the liver of Fmo5/
mice, aldolase B, ketohexokinase and GPD1, are involved in
carbohydrate metabolism. Aldolase B is a glycolytic enzyme that
catalyzes the production of glyceraldehyde 3-phosphate and
dihydroxyacetone phosphate (DHAP), from fructose 1,6-bispho-
sphate. Ketohexokinase (or fructokinase) catalyzes the conversion
of fructose to fructose 1-phosphate, which can be converted to
glyceraldehyde and DHAP in a reaction catalyzed by aldolase B.
Both glyceraldehyde and DHAP can be converted to the glycolyticintermediate glyceraldehyde 3-phosphate, via reactions catalyzed
by triose kinase and triose phosphate isomerase respectively. For
glycolysis to proceed glyceraldehyde 3-phosphate must be
converted to 1,3-bisphosphoglycerate, in a reaction which requires
NAD+ and produces NADH. GPD1 catalyzes the oxidation of
cytosolic NADH by DHAP to produce NAD+, which re-enters
glycolysis, and glycerol 3-phosphate, which can be combined with
fatty acids to form triglycerides. The expected consequence of the
down regulation of aldolase B, ketohexokinase and GPD1 in the
liver of Fmo5/ mice is slowing of the entry of fructose into
glycolysis and of the metabolism of glucose via glycolysis and, thus,
a decrease the amount of pyruvate produced by this pathway. This
is supported by the ﬁnding that the plasma concentration of
pyruvate was lower in KO than in WT mice. In addition, down
regulation of GPD1 would be expected to moderate the biosyn-
thesis of triglycerides, via its effect on production of glycerol 3-
phosphate, providing a potential explanation for the reduced fat
deposits of these animals.
Aldolase B can catalyze the reverse reaction, producing fructose
1,6-bisphosphate from DHAP and glyceraldehyde 3-phosphate, a
key step in gluconeogenesis. Down regulation of aldolase B would,
therefore, be expected to slow both glycolysis and gluconeogene-
sis, suggesting that Fmo5/mice do not increase gluconeogenesis
in response to a lower plasma concentration of glucose. The
similarity in liver glycogen content of the KO and WT mice
indicates that the former do not respond to lower plasma glucose
by increasing the mobilization of glucose from glycogen.
The lower plasma concentration of cholesterol in Fmo5/mice
was accompanied by lower abundance in liver of HMG-CoA
synthase 1, which catalyzes the ﬁrst committed step in isoprenoid
biosynthesis. It has been shown that modulation of HMG-CoA
synthase 1 activity inﬂuences cholesterol biosynthesis [37,38] and
the enzyme is negatively regulated, via a feedback mechanism, in
response to cholesterol feeding [39]. In contrast, in Fmo5/ mice
down regulation of the amount of HMG-CoA synthase 1 occurred in
the context of lower, not higher, plasma cholesterol. However, the
induction in Fmo5/ mice of mRNAs encoding HMG-CoA
reductase, which catalyzes the rate-limiting step in cholesterol
biosynthesis, squalene synthase, which catalyzes the ﬁrst step in
the pathway that produces cholesterol from farnesyl pyrophos-
phate, and the transcription factor SREBP-2 is a normal response to
low plasma cholesterol [40,41]. But, despite this, the concentration
of plasma cholesterol in the KO mice remained low. In Fmo5/
mice down regulation of HMG-CoA synthase 1 protein occurred in
the absence of a change in the amount of its mRNA, indicating that,
in these animals, regulation of expression of HMG-CoA synthase
1 was independent of transcription and also of that of other key
enzymes in the pathway.
Acetyl-CoA is a product of fatty acid and glucose catabolism.
Depending on the needs of a cell or organism, acetyl-CoA can be
used for energy production, by entering the citric acid cycle, or for
the biosynthesis of fatty acids, ketone bodies or cholesterol. The
concentration of cytosolic acetyl-CoA in the livers of KO and WT
mice was similar, suggesting that the impact on fat and cholesterol
production in the KO mice was primarily due to down regulation of
key synthetic enzymes, not to a shortage of the primary building
blocks.
The lower plasma concentration of pyruvate in the Fmo5/
mice could be explained by the down regulation in liver of the
glycolytic enzyme aldolase B (see above) and of ME1, which
catalyzes the production of pyruvate from malate. It has been
shown, in cell culture, that glucose, through the glycolytic product
pyruvate, induces the amount and activity of ME1 [42]. Thus, in
Fmo5/ mice reduction in the production of pyruvate, as a
consequence of down regulation of aldolase B, might contribute to
the down regulation of ME1.
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transcription, stabilization of nuclear RNA and degradation of
cytoplasmic RNA; and it is regulated independently in response to
a high-carbohydrate diet and by thyroid hormone [43]. In Fmo5/
mice the abundance of ME1 is apparently regulated by a different
mechanism: either via a block in the translation of the mRNA or an
increase in the rate of degradation of the protein.
The reaction catalyzed by ME1 is an important source of NADPH
for use in anabolic reactions, including the biosynthesis of fatty
acids and cholesterol. Repression of ME1 decreases the cellular
concentration of NADPH [42,44]. Reduction in the concentration of
NADPH, as a consequence of down regulation of ME1, would be
expected to moderate the biosynthesis of both fatty acids and
cholesterol, thus providing a potential explanation for the reduced
fat deposits and lower plasma cholesterol that are characteristic of
the metabolic phenotype of Fmo5/ mice.
In liver biopsies of type-2 diabetics, FMO5 was one of 134 genes
found to be repressed [45]. The phenotype of the Fmo5/ mice
reveals that in the absence of FMO5 weight and plasma glucose are
reduced. This suggests strongly that the reduction in the
expression of FMO5 in type-2 diabetics is a response to this
aberrant metabolic condition in an attempt to restore homeostasis.
Another FMO KO mouse line, one that lacks genes encoding
FMO1, FMO2 and FMO4, also exhibits a lean phenotype, with
reduced body weight and fat deposits [25]. However, there are
distinct differences between this KO mouse line and Fmo5/mice.
The phenotype of mice lacking Fmo1, Fmo2 and Fmo4 genes, which
is attributed to lack of FMO1, is evident from as early as six weeks
of age and is characterized by enhanced whole-body energy
expenditure and REE with no change in RER (indicating an increase
in both fat and carbohydrate oxidation), increased capacity for
exercise, elevated fatty acid oxidation in skeletal muscle, but not in
WAT, higher plasma glucose and evidence for the operation of a
futile fuel cycle in WAT [25]. In contrast, the phenotype of Fmo5/
mice is age-related, becoming apparent only after 20 weeks of age,
and is characterized by lower plasma concentrations of glucose
and cholesterol, fatty acid oxidation that is reduced in skeletal
muscle but elevated in WAT, and no increase in physical activity. In
common with mice that lack FMO1, FMO2 and FMO4, mice that
lack FMO5 exhibit enhanced whole-body energy expenditure and
REE, but have increased RER, indicating a switch from fat to
carbohydrate oxidation. Thus, both FMO5 and FMO1 are metabolic
regulators. However, whereas FMO1 acts as a regulator of energy
homeostasis [25], our results indicate that FMO5 regulates
metabolic ageing via pleiotropic effects. These include positive
modulation of cholesterol biosynthesis, via promoting the
expression in liver of enzymes involved in the cholesterol
biosynthetic pathway and the production of NADPH, and also
promoting the hepatic expression of enzymes involved in
glycolysis/gluconeogenesis and in the formation of glycerol 3-
phosphate for the biosynthesis of triglycerides.
FMO5 is classiﬁed as an oxidoreductase and it is possible that its
effects are mediated via modulation of the cellular redox state.
However, in vivo substrates of FMO5 have yet to be identiﬁed and
the mechanism by which the enzyme exerts its pleiotropic effects
remains to be established.
Our results have potential implications for humans, indicating
that interindividual variation in FMO5 expression [20–22] may
contribute to differences in fat deposits and plasma cholesterol and
that induction of FMO5 expression by some therapeutics [19] may
have adverse effects on the metabolic health of patients.
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